Adult Kidney Neoplastic Pathology

  • Eleni A. Karatrasoglou
  • Andreas C. Lazaris
  • Vasileios Spapis
  • Dionysia N. Zouki


A pathologic report for renal tubular cancer nephrectomy specimens should include the following information: type of procedure, specimen laterality, tumor site, tumor size (largest tumor, if multiple), tumor focality, macroscopic extent of tumor, histologic subtype, sarcomatoid features, tumor necrosis (any amount), WHO/ISUP nucleolar/nuclear grade, microscopic tumor extension, margins, lymph-vascular invasion (in addition to invasion of renal vein and its muscle containing segmental branches and inferior vena cava), pathologic staging (pTNM), pathologic findings in nonneoplastic kidney, and other tumors or tumorlike lesions (such as cysts, papillary adenomas).

A pathologic report for renal tubular cancer biopsy specimens should include the following information: type of procedure, specimen laterality, histologic subtype, sarcomatoid features, and WHO/ISUP nucleolar/nuclear grade.

Four major common renal cell tumor subtypes can be distinguished based on morphologic and genetic characteristics [i.e., clear cell renal cell carcinoma (RCC), papillary RCC, chromophobe RCC, and oncocytoma]; WHO/ISUP nucleolar/nuclear grading system is implemented in the first two of the above subtypes.

Based on clinicopathologic findings (such as histologic tumor type, bilateral tumor location, and tumor multifocality), hereditary syndromes (i.e., Birt-Hogg-Dubé, hereditary leiomyomatosis renal cell carcinoma, hereditary papillary renal carcinoma, tuberous sclerosis, and von Hippel-Lindau syndrome) can be suspected and relevant investigation can be proposed. Cytogenetic analysis can confirm the diagnosis of MiTF/TFE family translocation-associated carcinoma.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Algaba F (2013) Immunohistochemistry in renal cell carcinoma. What’s new?-What’s new in uropathology? Handout. Working group symposium. 25th European Congress of Pathology. ESPGoogle Scholar
  2. Algaba F, Akaza H, Lopez-Beltran A, Martignoni G et al (2011) Current pathologic keys of renal cell Carcinoma. Eur Urol 60(4):634–643CrossRefPubMedGoogle Scholar
  3. Armstrong AJ, Halabi S, Eisen T et al (2016) Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial. Lancet Oncol 17:378–388CrossRefPubMedGoogle Scholar
  4. Bissler JJ, Kingswood JC, Radzikowska E et al (2016) Everolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: extension of a randomized controlled trial. Nephrol Dial Transplant 31(1):111–119CrossRefPubMedGoogle Scholar
  5. Campbell S, Lane B (2012) Malignant renal tumors. In: Kavoussi L, Novick A, Partin A, Peters C (eds) Campbell-Walsh urology, 10th edn. Saunders, Philadelphia, pp 1413–1474CrossRefGoogle Scholar
  6. Cheville JC, Lohse CM, Sukov WR et al (2012) Chromophobe renal cell carcinoma: the impact of tumor grade on outcome. Am J Surg Pathol 36:851–856CrossRefPubMedGoogle Scholar
  7. Choueiri TK, Escudier B, Powles T et al (2015) Cabozantinib versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373:1814–1823CrossRefPubMedPubMedCentralGoogle Scholar
  8. Choueiri TK, Escudier B, Powles T et al (2016) Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open label, phase 3 trial. Lancet Oncol 17:917–927CrossRefPubMedGoogle Scholar
  9. Cindolo L, de la Taille A, Schips L et al (2005) Chromophobe renal cell carcinoma: comprehensive analysis of 104 cases from multicenter European database. Urology 65(4):681–686CrossRefPubMedGoogle Scholar
  10. Clague J, Lin J, Cassidy A et al (2009) Family history and risk of renal cell carcinoma: results from a case-control study and systematic meta-analysis. Cancer Epidemiol Biomark Prev 18(3):801–807CrossRefGoogle Scholar
  11. Crépel M, Jeldres C, Perrotte P et al (2010) Nephron-sparing surgery is equally effective to radical nephrectomy for T1BN0M0 renal cell carcinoma: a population-based assessment. Urology 75:271–275CrossRefPubMedGoogle Scholar
  12. Eble JN (1998) Angiomyolipoma of kidney. Semin Diagn Pathol 15(1):21–40PubMedGoogle Scholar
  13. Escudier B, Eisen T, Stadler WM et al (2007a) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125–134CrossRefPubMedGoogle Scholar
  14. Escudier B, Pluzanska A, Koralewski P et al (2007b) Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370:2103–2111CrossRefPubMedGoogle Scholar
  15. Escudier B, Porta C, Schmidinger M et al (2016) Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow up. Ann Oncol 27(Suppl.5):v58–v68CrossRefPubMedGoogle Scholar
  16. Heng DY, Xie W, Regan MM et al (2009) Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 27:5794–5799CrossRefPubMedGoogle Scholar
  17. Heng DY, Xie W, Regan MM et al (2013) External validation and comparison with other models of the International Metastatic Renal- Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol 14:141–148CrossRefPubMedPubMedCentralGoogle Scholar
  18. Hes O, Petersson F, Kuroda N et al (2013) Renal hybrid oncocytic/chromophobe tumors- A review. Histol Histopathol 28:1257–1264PubMedGoogle Scholar
  19. Hock LM, Lynch J, Balaji KC (2002) Increasing incidence of all stages of kidney cancer in the last 2 decades in the United States: an analysis of surveillance, epidemiology and end results program data. J Urol 167(1):57–60CrossRefPubMedGoogle Scholar
  20. Hudes G, Carducci M, Tomczak P et al (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356:2271–2281CrossRefPubMedGoogle Scholar
  21. Jayson M, Sanders H (1998) Increased incidence of serendipitously discovered renal cell carcinoma. Urology 51:203–205CrossRefPubMedGoogle Scholar
  22. Junker K, Ficarra V, Kwon ED et al (2012) Potential role of genetic markers in the management of kidney cancer. Eur Urol 63(2):333–340CrossRefPubMedGoogle Scholar
  23. Kantarjian HM, Wolff RA (eds) (2010) The MD Anderson manual of medical oncology Chapter 35, 3rd edn. McGraw-Hill Medical, New York, p 916Google Scholar
  24. Konety B, Vaena D, Williams R (2013) Renal parenchymal neoplasms. In: McAninch J, Lue T (eds) Smith and Tanagho’s general urology, 18th edn. McGraw-Hill, New York, pp 330–340Google Scholar
  25. Levi F, Ferlay J, Galeone C et al (2008) The changing pattern of kidney cancer incidence and mortality in Europe. BJU Int 101(8):949–958CrossRefPubMedGoogle Scholar
  26. Ljungberg B (2016) Renal cell carcinoma. In: European Association of Urology Guidelines. European Association of Urology. Available via Accessed 26 Feb 2017
  27. Magi-Galluzzi C, Zhou M (2010) Ureter, urinary bladder and kidney chapter 10. In: Gattuso P, Reddy VB, David O, Spitz DJ, Haber MH (eds) Differential diagnosis in surgical pathology, 2nd edn. Saunders, Elsevier, Philadelphia, pp 487–538CrossRefGoogle Scholar
  28. Margulis V, Matin S, Wood C (2012) Benign renal tumors. In: Kavoussi L, Novick A, Partin A, Peters C (eds) Campbell-Walsh urology, 10th edn. Saunders, Philadelphia, pp 1496–1501Google Scholar
  29. Miller BA, Scoppa SM, Feuer EJ (2006) Racial/ethnic patterns in lifetime and age-conditional risk estimates for selected cancers. Cancer 106(3):670–682CrossRefPubMedGoogle Scholar
  30. Moch H, Humphrey PA, Ulbright TM, Reuter VE (eds) (2016) WHO classification of tumours of the urinary system and male genital organs. IARC, LyonGoogle Scholar
  31. Motzer RJ, Hutson TE, Tomczak P et al (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115–124CrossRefPubMedGoogle Scholar
  32. Motzer RJ, Escudier B, Oudard S et al (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372:449–456CrossRefPubMedGoogle Scholar
  33. Motzer RJ, Hutson TE, Cella D et al (2013) Pazopanib versus sunitinib in metastatic renal cell carcinoma. N Engl J Med 369:722–731CrossRefPubMedGoogle Scholar
  34. Motzer RJ, Barrios CH, Kim TM et al (2014a) Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma. J Clin Oncol 32:2765–2772CrossRefPubMedPubMedCentralGoogle Scholar
  35. Motzer RJ, Porta C, Vogelzang NJ et al (2014b) Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial. Lancet Oncol 15:286–296CrossRefPubMedPubMedCentralGoogle Scholar
  36. Motzer RJ, Escudier B, McDermott DF et al (2015) Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373:1803–1813CrossRefPubMedPubMedCentralGoogle Scholar
  37. Mues AC, Palacios JM, Haramis G et al (2010) Contemporary experience in the management of angiomyolipoma. J Endourol 24(11):1883–1886CrossRefPubMedGoogle Scholar
  38. Murphy WM, Grignon DJ, Perlman EJ (2004) Tumors of the kidney, bladder and related urinary structures AFIP Atlas of Tumor Pathology Series 4, WashingtonGoogle Scholar
  39. Murray TE, Doyle F, Lee M (2015) Transarterial embolization of angiomyolipoma: a systematic review. J Urol 194(3):635–639CrossRefPubMedGoogle Scholar
  40. Novara G, Ficarra V, Antonelli A et al (2010) Validation of the 2009 TNM version in a large multi-institutional cohort of patients treated for renal cell carcinoma: are further improvements needed? Eur Urol 58:588–595CrossRefPubMedGoogle Scholar
  41. Ouzaid I, Autorino R, Fatica R et al (2014) Active surveillance for renal angiomyolipoma: outcomes and factors predictive of delayed intervention. BJU Int 114(3):412–417PubMedGoogle Scholar
  42. Oxley JD, Sullivan J, Mitchelmore A et al (2007) Metastatic renal oncocytoma. J Clin Pathol 60(6):720–722CrossRefPubMedPubMedCentralGoogle Scholar
  43. Paner GP, Turk TM, Clark JI, Lindgren V, Picken MM (2005) Passive seeding in metanephric adenoma: a review of pseudometastatic lesions in perinephric lymph nodes. Arch Pathol Lab Med 129(10):1317–1321PubMedGoogle Scholar
  44. Paner GP, Amin MB, Alvarado-Cabrero I et al (2010) A novel tumor grading scheme for chromophobe renal cell carcinoma: prognostic utility and comparison with Fuhrman nuclear grade. Am J Surg Pathol 34:1233–1240CrossRefPubMedGoogle Scholar
  45. Pignot G, Elie C, Conquay S et al (2007) Survival analysis of 130 patients with papillary renal cell carcinoma: prognostic utility of type 1 and type 2 subclassification. Urology 69:230–235CrossRefPubMedGoogle Scholar
  46. Poulakis V, Witsch U, de Vries R et al (2003) Quality of life after surgery for localized renal cell carcinoma: comparison between radical nephrectomy and nephron-sparing surgery. Urology 62:814–820CrossRefPubMedGoogle Scholar
  47. Przybycin CG, McKenney JK, Reynolds JP et al (2014) Rhabdoid differentiation is associated with aggressive behavior in renal cell carcinoma: a clinicopathologic analysis of 76 cases with clinical follow-up. Am J Surg Pathol 38(9):1260–1265PubMedGoogle Scholar
  48. Ramon J, Rimon U, Garniek A et al (2009) Renal angiomyolipoma: long-term results following selective arterial embolization. Eur Urol 55(5):1155–1161CrossRefPubMedGoogle Scholar
  49. Rini BI, Campbell SC, Escudier B (2009) Renal cell carcinoma. Lancet 373:1119–1132CrossRefPubMedGoogle Scholar
  50. Rini BI, Escudier B, Tomczak P et al (2011) Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 378:1931–1939CrossRefPubMedGoogle Scholar
  51. Romis L, Cindolo L, Patard JJ et al (2004) Frequency, clinical presentation and evolution of renal oncocytomas: Multicentric experience from a European database. Eur Urol 45:53–57CrossRefPubMedGoogle Scholar
  52. Ross H, Martignoni G, Argani P (2012) Renal cell carcinoma with clear cell and papillary features. Arch Pathol Lab Med 136:391–399CrossRefPubMedGoogle Scholar
  53. Sheth S, Scatarige JC, Horton KM et al (2001) Current concepts in the diagnosis and management of renal cell carcinoma: role of multidetector ct and three-dimensional CT. Radiographics 21:S237–S254CrossRefPubMedGoogle Scholar
  54. Srigley JR, Delahunt B, Eble JN et al (2013) The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia. Am J Surg Pathol 37:1469–1489CrossRefPubMedGoogle Scholar
  55. Sternberg CN, Davis ID, Mardiak J et al (2010) (2010) Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 28:1061–1068CrossRefPubMedGoogle Scholar
  56. Störkel S, Eble JN, Adlakha K et al (1997) Classification of renal cell carcinoma: Workgroup No. 1. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer 80(5):987–989CrossRefPubMedGoogle Scholar
  57. Sukov WR, Lohse CM, Leibovich BC et al (2012) Clinical and pathological features associated with prognosis in patients with papillary renal cell carcinoma. J Urol 187(1):54–59CrossRefPubMedGoogle Scholar
  58. Tannir NM, Jonasch E, Albiges L et al (2016) Everolimus versus sunitinib prospective evaluation in metastatic non-clear cell renal cell carcinoma (ESPN): a randomized multicenter phase 2 trial. Eur Urol 69:866–874CrossRefPubMedGoogle Scholar
  59. Toro JR, Glenn G, Duray P et al (1999) Birt-Hogg-Dubé syndrome: A novel marker of kidney neoplasia. Arch Dermatol 135:1195–1202PubMedGoogle Scholar
  60. Truong LD, Shen SS (2011) Immunohistochemical diagnosis of renal neoplasms. Arch Pathol Lab Med 135:92–109PubMedGoogle Scholar
  61. Urge T, Hes O, Ferda J et al (2010) Typical signs of oncocytic papillary renal cell carcinoma in everyday clinical praxis. World J Urol 28:513–517CrossRefPubMedGoogle Scholar
  62. Van Poppel H, Da Pozzo L, Albrecht W et al (2011) A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. Eur Urol 59:543–552CrossRefPubMedGoogle Scholar
  63. Vera-Badillo FE, Conde E, Duran I (2012) Chromophobe renal cell carcinoma: a review of an uncommon entity. Int J Urol 19:894–900CrossRefPubMedGoogle Scholar
  64. Volpe A, Novara G, Antonelli A et al (2012) Chromophobe renal cell carcinoma (RCC): oncological outcomes and prognostic factors in a large multicentre series. BJU Int 110:76–83CrossRefPubMedGoogle Scholar
  65. Wang H-Y, Mills SE (2005) KIT and RCC are useful in distinguishing chromophobe renal cell carcinoma from the granular variant of clear cell renal cell carcinoma. Am J Surg Pathol 29(5):640–646CrossRefPubMedGoogle Scholar
  66. Zhou M, Magi-Galluzzi C (2007) Genitourinary pathology, foundations in diagnostic pathology. Churchill Livingstone, PhiladelphiaGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Eleni A. Karatrasoglou
    • 1
  • Andreas C. Lazaris
    • 1
  • Vasileios Spapis
    • 1
  • Dionysia N. Zouki
    • 1
  1. 1.AthensGreece

Personalised recommendations